摘要
背景:间充质干细胞是干细胞家族的重要成员,近年来逐渐应用于风湿性疾病的治疗。目的:分析国内间充质干细胞移植用于治疗4种风湿性疾病的有效性及安全性。方法:主要以"间充质干细胞"、"系统性红斑狼疮"、"类风湿关节炎"、"肌炎"、"系统性硬化症"为检索词,计算机检索中国期刊全文数据库、中文科技期刊数据库,并辅以手工检索,全面收集2004年至2013年国内核心期刊发表的相关文献。结果与结论:对其中12篇符合标准的文献进行分析,12篇文献共报道76例风湿性疾病患者,其中系统性红斑狼疮46例(61%),类风湿关节炎21例(28%),多发性肌炎/皮肌炎8例(11%),系统性硬化症1例(1%),76例患者移植后临床症状及实验室检查结果均有不同程度的改善,其中未涉及患者出现不良反应及并发症的报道,随访期间7例(9%)出现病情复发,其中1例死亡。说明间充质干细胞移植治疗风湿性疾病的总体有效性及安全性较高,但仍需更多的临床病例、随访资料和随机对照试验证实。
BACKGROUND： Mesenchymal stem cell is an important member of stem cell family, and it is increasingly used in the treatment of rheumatic diseases in recent years. OBJECTIVE： To analyze the emcacy and safety of mesenchymal stem cell transplantation in patients with rheumatic disease in China. METHODS： A computer-based search was conducted in Chinese Journal Full-text database and China Science and Technology Journal Database for relevant articles published from 2004 to 2013. Manual searching was also done. Key words were ＂mesenchymal stem cell＂, ＂systemic lupus erythematosus＂, ＂rheumatoid arthritis＂, ＂myositis＂ and ＂systemic sclerosis＂ in Chinese. RESULTS AND CONCLUSION： Twelve papers were selected and analyzed in this study. A total of 76 patients with rheumatic disease were reported in these 12 papers, including 46 （61%） cases of systemic lupus erythematosus, 21 （28%） of rheumatoid arthritis, 8 （11%） of polymyositis/dermatomyositis and 1 （1%） of systemic sclerosis. All of the 76 patients＇ clinical symptoms and laboratory test results were improved after treatment and no adverse reactions or complications occur. During the follow-up, 7 （9%） of the 76 patients relapsed, including 1 death case. These findings indicate that mesenchymal stem cell transplantation in patients with rheumatic disease is efficient and safe; however, more case-control studies, cohort studies and clinical trials are required to confirm the result.
出处
《中国组织工程研究》
CAS
CSCD
2014年第14期2263-2268,共6页
Chinese Journal of Tissue Engineering Research
基金
辽宁省科学技术计划项目(2011225015)
沈阳市科学技术项目(F12-277-1-85)~~
